Ozanimod

Pharmacology

• Ozanimod is a sphingosine-1-phosphate receptor (S1PR) modulator
• It sequesters lymphocytes within lymph nodes
• It acts on S1PR1 and S1PR5 

Indications

Benefits

Dosing

Side effects

Pre-treatment precautions

Contraindications

Complications

Acronym

References

1. Lamb YN. Ozanimod: first approval. Drugs 2020 (Epub ahead of print).
2. Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 2017; 14:859-873.
3. Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol 2020; 19:336-347.
4. Comi G, Kappos L, Selmaj KW, et al; SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 2019; 18:1009-1020.
5. Cohen JA, Arnold DL, Comi G, et al; RADIANCE Study Group. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15:373-381.
6. And 1 more. Subscribe to see the full list

Related checklists

• Siponimod